LXRX
Lexicon Pharmaceuticals Inc
1.70$
-4.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -17.0% | +81.9% | -10.5% | -14.0% | -7.1% | -0.3% | -24.2% | -8.7% | -10.2% | +45.3% | -7.0% | |
| – | -21.0% | +106.5% | -12.0% | -16.3% | -8.3% | -0.2% | -41.0% | -15.5% | -16.8% | +82.6% | +5.7% | |
| – | +6.4% | +329.5% | -63.1% | -3.0% | +92.9% | -5.7% | -66.0% | +132.4% | -30.9% | +11.0% | +7.4% | |
| – | -22.2% | +109.1% | -12.8% | -16.6% | -7.9% | -18.1% | -28.7% | -16.6% | -17.0% | +77.3% | +11.7% | |
| – | +217.6% | +51.1% | +71.7% | +10.5% | +20.0% | +1,266.2% | -95.4% | +6.9% | +2.1% | +394.1% | -86.1% | |
| – | +13.4% | +34.9% | +13.8% | +8.7% | -63.7% | -13.0% | -16.4% | -6.0% | +77.8% | -1.8% | +333.3% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | |
| – | -0.5% | -5.8% | +3.9% | +6.9% | +6.9% | +14.5% | -44.9% | -10.8% | -9.7% | -14.8% | +14.5% | |
| – | -2.2% | -25.8% | +19.1% | +29.3% | +25.5% | +144.6% | -68.5% | -37.7% | -3.9% | -52.6% | +48.6% | |
| – | +0.0% | +0.0% | +0.0% | +0.8% | -9.7% | +3,568.1% | -97.9% | +80.6% | +279.8% | -73.7% | +0.0% | |
| – | +19.5% | -43.9% | +51.5% | +16.2% | +4.2% | -27.8% | -44.8% | -35.6% | -18.8% | -2.8% | -21.8% | |
| – | +0.2% | +0.4% | -0.4% | +0.4% | +0.4% | -41.5% | -4.3% | +0.7% | -12.6% | +0.6% | +3.5% | |
| – | -33.3% | +210.2% | -16.9% | -25.6% | -18.2% | -15.7% | +5.2% | -7.2% | -10.5% | +88.6% | -14.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.2% | +26.7% | +16.3% | +0.0% | +0.2% | +0.4% | 0.0% | +0.0% | +10.1% | +9.3% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.